Development trends for monoclonal antibody cancer therapeutics

Nature Reviews Drug Discovery

Volumn 6, Issue 5, 2007, Pages 349-356

  Reichert, Janice M ^a   Valge Archer, Viia E ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AURISTATIN PE; BEVACIZUMAB; CALICHEAMICIN; CETUXIMAB; CP 675206; CP 751871; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENOSUMAB; DOXORUBICIN; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IPILIMUMAB; MAYTANSINE; METHOTREXATE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VECTIBIX; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; HEAD AND NECK CANCER; HUMAN; IMMUNOSTIMULATION; INHIBITION KINETICS; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECEPTOR BLOCKING; TUMOR CELL; TUMOR VASCULARIZATION; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG INDUSTRY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 34247876138     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2241     Document Type: Article

References (46)

1. Reichert, J. M., Rosensweig, C. J., Faden, L. B. & Dewitz, M. C. Monoclonal antibody successes in the clinic. Nature Biotech. 23 1073-1078 (2005).
2. Lin, M. Z., Teitell, M. A. & Schiller, G. J. The evolution of antibodies into versatile tumor-targeting agents. Clin. Cancer Res. 11, 129-38 (2005).
3. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nature Rev. Cancer 1, 118-129 (2001).
4. Carter, P., Smith, L. & Ryan, M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr. Relat. Cancer 11, 659-687 (2004).
5. Punt, C. J. et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Lancet 360, 671-677 (2002).
6. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
7. Ober, R. J., Radu, C. G., Ghetie, V. & Ward, E. S. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int. Immunol. 13, 1551-1559 (2001).
8. Shawler, D. L, Bartholomew, R. M., Smith, L. M. & Dillman, R. O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135, 1530-1535 (1985).
9. Kuus-Reichel, K. et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1, 365-372 (1994).
10. Kipps, T. J., Parham, P., Punt, J. & Herzenberg, L. A. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 161, 1-17 (1985).
11. Presta, L. G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Del. Rev. 58 640-656 (2006).
12. Morrison, S. L., Johnson, M. J., Herzenberg, L. A. & Oi, V. T. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant domains. Proc. Natl Acad. Sci. USA 81, 6851-6855 (1984).
13. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
14. Reichmann, L., Clark, M., Waldmann. H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323-327 (1988).
15. Lonberg, N. Human antibodies from transgenic animals. Nature Biotech. 23, 1117-1125 (2005).
16. McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990).
17. Payne, G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 3, 207-212 (2003).
18. Schrama, D., Reisfeld, R. A. & Becker, J. C. Antibody targeted drugs as cancer therapeutics. Nature Rev. Drug Discov. 5, 147-159 (2006).
19. Milenic, D. E., Brady, E. D. & Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nature Rev. Drug Discov. 3, 488-499 (2004).
20. Sharkey, R. M. & Goldenberg, D. M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46, 115S-127S (2005).
21. Goldenberg, D. M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693-713 (2002).
22. Frankel, A. E., Kreitman, R. J. & Sausville, E. A. Targeted toxins. Clin. Cancer Res. 6, 326-334 (2000).
23. Morell, A., Terry, W. D. & Waldmann, T. A. Metabolic properties of IgG subclasses in man J. Clin. Invest. 49, 673-680 (1970).
24. Adams, G. P. & Weiner, L. M. Monoclonal antibody therapy of cancer. Nature Biotech. 23, 1147-1157 (2005).
25. Stern, M. & Herrmann, R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit. Rev. Oncol. Hematol. 54, 11-29 (2005).
26. Trikha, M., Yan, L. & Nakada M. T. Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol. 13, 609-614 (2002).
27. Gelderman, K. A., Tomlinson, S., Ross, G. D. & Gorter, A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25, 158-164 (2004).
28. Bruggeman, M. et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351-1361 (1987).
29. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
30. Gennari, R. et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10, 5650-5655 (2004).
31. Janas, E. et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139, 439-446 (2005).
32. Scott, A. M. et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 60, 3254-3261 (2000).
33. Harris, M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5, 292-302 (2004).
34. Spicer, J. Technology evaluation: Nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr. Opin. Mol. Ther. 7 182-191 (2005).
35. Nahta, R. & Esteva, F. J. Herceptin: Mechanisms of action and resistance. Cancer Lett. 232, 123-138 (2006).
36. Arnould, L. et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94, 259-267 (2006).
37. Salgaller, M. L. Technology evaluation: Bevacizumab, Genentech/Roche. Curr. Opin. Mol. Ther. 5, 657-667 (2003).
38. Pukac, L. et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92, 1430-1441 (2005).
39. Melero, I. et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nature Rev. Cancer 7, 95-106 (2007).
40. Leach, D.R., Krummel, H.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (2006).
41. Zeidler, R. et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163, 1246-1252 (1999).
42. Baker, M. Upping the ante on antibodies. Nature Biotech. 23, 1065-1072 (2005).
43. Hoogenboom, H. R. Selecting and screening recombinant antibody libraries. Nature Biotech. 23, 1105-1116 (2005).
44. Carter, P. Potent antibody therapeutics by design. Nature Rev. Immunol. 6, 343-357 (2006).
45. Dancey, J. E. & Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Rev. Drug Discov. 5, 649-659 (2006).
46. Jimeno, A. & Hidalgo, M. Multitargeted therapy: Can promiscuity be praised in an era of political correctness? Crit. Rev. Oncol. Hematol. 59, 150-158 (2006).